Compare PAR & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAR | COLL |
|---|---|---|
| Founded | 1968 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 699.1M | 752.3M |
| IPO Year | 1995 | 2015 |
| Metric | PAR | COLL |
|---|---|---|
| Price | $21.94 | $24.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 8 |
| Target Price | $26.63 | ★ $44.88 |
| AVG Volume (30 Days) | ★ 1.0M | 613.1K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | $455,547,000.00 | ★ $780,567,000.00 |
| Revenue This Year | $17.26 | $6.73 |
| Revenue Next Year | $8.27 | $1.37 |
| P/E Ratio | ★ N/A | $39.01 |
| Revenue Growth | ★ 30.16 | N/A |
| 52 Week Low | $11.59 | $21.43 |
| 52 Week High | $40.54 | $50.79 |
| Indicator | PAR | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 75.56 | 59.64 |
| Support Level | $12.64 | $21.67 |
| Resistance Level | $22.48 | $26.39 |
| Average True Range (ATR) | 1.04 | 0.84 |
| MACD | 0.38 | 0.15 |
| Stochastic Oscillator | 90.80 | 57.32 |
PAR Technology Corp is a foodservice technology company providing omnichannel cloud-based software and hardware solutions to the restaurant industry in three restaurant categories - quick service, fast casual, and table service - and the retail industry, including convenience and fuel retailers (C-Stores). Its product and service offerings include point-of-sale, customer engagement and loyalty, digital ordering and delivery, operational intelligence, payment processing, hardware, and related technologies, solutions, and services. The company generates revenue from subscription service, Sale of Hardware products, and Professional Service.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.